GlassScriptPhysician profile
Christopher R Rawls
NPI 1114488095
$2,172.38
in general payments reported to CMS, 2019-2025
27 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.27 · 2020: $40.25 · 2022: $194 · 2023: $550 · 2024: $782 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $366.27 | 2023-2025 | |
| Novo Nordisk INC | $295.08 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $145.03 | 2022-2025 | Evenity, Prolia |
| Lilly USA, LLC | $124.68 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $122.56 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $109.85 | 2022-2024 | Belsomra, Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $99.63 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $97.32 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $94.56 | 2024 | Voquezna |
| Lundbeck LLC | $76.55 | 2024-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $74.53 | 2022-2025 | Zoryve, Livalo, Seglentis |
| Otsuka America Pharmaceutical, INC. | $70.38 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $60.77 | 2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $52.66 | 2024 | Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.71 | 2024-2025 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $43.39 | 2024-2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $42.70 | 2023-2024 | Eliquis |
| Advanced Respiratory, INC | $40.25 | 2020 | |
| Exact Sciences Corporation | $38.46 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $37.28 | 2025 | |
| Shield Therapeutics INC | $34.50 | 2023-2024 | Accrufer |
| Idorsia Pharmaceuticals US INC | $17.61 | 2022 | |
| Esperion Therapeutics, INC. | $17.14 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $16.52 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.27 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.15 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rawls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.